335 related articles for article (PubMed ID: 28133107)
21. An Insight into Deficient Mismatch Repair Colorectal Cancer Screening in a Romanian Population-A Bi-Institutional Pilot Study.
Lungulescu C; Croitoru VM; Volovat SR; Cazacu IM; Turcu-Stiolica A; Gheonea DI; Sur D; Lungulescu CV
Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441055
[No Abstract] [Full Text] [Related]
22. [Correlation between mismatch repair proteins status and clinicopathological characteristics in sporadic colorectal cancer patients].
Xiao ZT; Zhang RX; Zhao Y; Peng JH; Lu SX; Zhang HZ; Ding PR; Wu XJ; Lu ZH; Li LR; Wan DS; Pan ZZ; Chen G
Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(16):1248-1251. PubMed ID: 28441855
[No Abstract] [Full Text] [Related]
23. Comprehensive Clinicopathologic Analysis for Mismatch Repair Protein Expression in Unselected Endometrial Carcinoma Patients With an Emphasis on the Role of MLH1 Deficiency.
Huang SW; Lin H; Huang CC; Ou YC; Fu HC; Tsai CC; Changchien CC; Wu CH
Int J Gynecol Pathol; 2022 Jul; 41(4):407-416. PubMed ID: 34347667
[TBL] [Abstract][Full Text] [Related]
24. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
25. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.
Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS
Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048
[TBL] [Abstract][Full Text] [Related]
26. Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer.
van der Heide DM; Turaga KK; Chan CHF; Sherman SK
J Surg Res; 2021 Oct; 266():104-112. PubMed ID: 33989889
[TBL] [Abstract][Full Text] [Related]
27. Expression status of four mismatch repair proteins in patients with colorectal cancer: clinical significance in 1238 cases.
Chen L; Chen G; Zheng X; Chen Y
Int J Clin Exp Pathol; 2019; 12(10):3685-3699. PubMed ID: 31933757
[TBL] [Abstract][Full Text] [Related]
28. Accuracy of four mononucleotide-repeat markers for the identification of DNA mismatch-repair deficiency in solid tumors.
Takehara Y; Nagasaka T; Nyuya A; Haruma T; Haraga J; Mori Y; Nakamura K; Fujiwara T; Boland CR; Goel A
J Transl Med; 2018 Jan; 16(1):5. PubMed ID: 29329588
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres.
Grant M; Haydon A; Au L; Wilkins S; Oliva K; Segelov E; Antill Y; Carne P; Ranchod P; Polglase A; Farmer C; Chin M; Wale R; Simpson P; Bell S; Skinner S; McMurrick P; Shapiro J
Int J Surg; 2018 Mar; 51():71-75. PubMed ID: 29367039
[TBL] [Abstract][Full Text] [Related]
30. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
[No Abstract] [Full Text] [Related]
31. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain.
Garcia-Carbonero R; González Astorga B; Vidal Tocino R; Contreras Toledo D; Pericay C; Fernández Montes A; Falcó E; González Cordero M; Reina Zoilo JJ; Alonso V; Rodríguez Salas N; Gil-Raga M; Santos C; Páez D; Anton-Pascual B; Aguilar F; Morales P
Clin Transl Oncol; 2024 Apr; 26(4):864-871. PubMed ID: 37651021
[TBL] [Abstract][Full Text] [Related]
32. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
[TBL] [Abstract][Full Text] [Related]
34. [Clinicopathological features and types of microsatellite instability in 1394 patients with colorectal cancer].
Li X; Liu H; Liang M; Chen H; Liang L
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Nov; 40(11):1645-1650. PubMed ID: 33243738
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analysis of DNA mismatch repair-deficient gastric cancer in a Japanese hospital-based population.
Ito T; Suzuki O; Kamae N; Tamaru JI; Arai T; Yamaguchi T; Akagi K; Eguchi H; Okazaki Y; Mochiki E; Ishida H
Jpn J Clin Oncol; 2021 May; 51(6):886-894. PubMed ID: 33728435
[TBL] [Abstract][Full Text] [Related]
36. The risk of developing a mismatch repair deficient colorectal cancer after undergoing cholecystectomy.
Halldorsson MO; Hauptmann M; Snaebjornsson P; Haraldsdóttir KH; Aspelund T; Gudmundsson EF; Gudnason V; Jonasson JG; Haraldsdottir S
Scand J Gastroenterol; 2018 Aug; 53(8):972-975. PubMed ID: 30010450
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
[TBL] [Abstract][Full Text] [Related]
38. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
Tougeron D; Sueur B; Zaanan A; de la Fouchardiére C; Sefrioui D; Lecomte T; Aparicio T; Des Guetz G; Artru P; Hautefeuille V; Coriat R; Moulin V; Locher C; Touchefeu Y; Lecaille C; Goujon G; Ferru A; Evrard C; Chautard R; Gentilhomme L; Vernerey D; Taieb J; André T; Henriques J; Cohen R;
Int J Cancer; 2020 Jul; 147(1):285-296. PubMed ID: 31970760
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma.
Bao F; Panarelli NC; Rennert H; Sherr DL; Yantiss RK
Am J Surg Pathol; 2010 Dec; 34(12):1798-804. PubMed ID: 21107085
[TBL] [Abstract][Full Text] [Related]
40. Tumor Budding
Karlberg M; Stenstedt K; Hallström M; Ragnhammar P; Lenander C; Edler D
Anticancer Res; 2018 Aug; 38(8):4713-4721. PubMed ID: 30061240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
